Organisation paid for research Program year 2025 Source: CMS Open Payments

Retinal Consultants Medical Group Admin

Neither a doctor nor a teaching hospital

Research payments

$739,668

428 payments

Through program year 2025, Retinal Consultants Medical Group Admin is reported as receiving $739,668 in research payments, across 428 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $409,651 377
2024 Research $97,748 21
2023 Research $230,964 21
2022 Research $119 1
2021 Research $1,186 8

Breakdown

Who paid Research payments · program years 2021–2025
  1. Boehringer Ingelheim International GmbH $451,980 380 payments
  2. Bayer HealthCare Pharmaceuticals Inc. $285,994 37 payments
  3. Boehringer Ingelheim Finland Ky $1,186 8 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $508 3 payments
Studies the money was for Research payments · program years 2021–2025
  1. CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitreal BI 764524 in patients with moderately severe to severe non-proliferative diabetic retinopathy $399,537 306 payments
  2. Runcaciguat Bay 1101042 - 2b in NPDR $230,964 21 payments
  3. BAY 1101042, A Phase 2 randomized, placebo-controlled, double-masked proof-of-concept study to investigate the efficacy and safety of runcaciguat (BAY 1101042) in patients with moderately severe to severe non-proliferative diabetic retinopathy. $55,029 16 payments
  4. BI 764524 Phase 2b $42,579 4 payments
  5. A Phase 2 Randomized, double-masked, active-controlled study to evaluate efficacy and safety of two regimens of BI 771716 against pegcetacoplan in patients with geographic atrophy secondary to age-related macular degeneration. $6,377 50 payments
  6. JADE: Phase II trial in patients with geographic atrophy: A randomized, double-masked, placebo-controlled, dose-finding study to evaluate the efficacy and safety of BI 1584862 $3,736 21 payments
  7. SRD/MRD/IIa $1,186 8 payments
  8. -Ph II (12mo treatment) $139 1 payment
  9. SRD MRD IIa $119 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record